The patenting of human genes in Australia remains under court review. As reported in the blog Patentology, an appeal of the Australian decision, Cancer Voices et al. v. Myriad Genetics Inc. et al., was filed on March 4, 2013 to a Full Bench of the Federal Court of Australia by the law firm of Maurice Blackburn on behalf of cancer survivor Yvonne D’Arcy. As reported in my February 19, 2013 post, the lower court upheld claims to isolated polynucleotides comprising all, or a portion of the BRCA1 locus or of a mutated BRCA1 locus. The polynucleotides can be RNA, DNA, cDNA and synthetic forms.
Subscribe to This Blog
Topics
- 35 U.S.C. 101
- AIA
- Bioethics
- Bioinformatics
- Biomarkers
- Business Method Patents
- Companion Diagnostics
- Diagnostic Methods
- Economics of Innovation
- FDA
- FDA Guidelines
- Gene Patents
- Genetic Testing
- Genomics
- Genomics and Personalized Medicine Act
- Health Care IT
- Infringement
- Medicare and Medicaid Services
- mHealth
- Patent Reform
- Payor Issues
- Personalized Medicine
- Petitions for Rehearing
- Privacy
- Prometheus
- Reimbursement
- Stem Cells
- UK/EP Patent Cases
- Uncategorized